Neonc Technologies Holdings Inc (NTHI)

$12.00 -0.11 (-0.91%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 9,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, h...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 663 7831
Address:
23975 Park Sorrento, Suite 205, Calabasas, United States
NeOnc_Technologies
NeOnc_Technologies Apr. 4 at 4:37 PM
$NTHI Driving Scientific Innovation into Commercial Impact NeOnc Technologies leverages a robust ecosystem of research, regulatory, and management expertise to accelerate the translation of cutting-edge science from the lab to the clinic and into the marketplace. Watch our full conversation with New To The Street TV here: https://bit.ly/NTTS-NeOncBreaksThroughBrainCancerTreatment #NeOncTechnologies #Quazar #BiotechInnovation #InvestorRelations #MarketImpact
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 2 at 6:10 PM
$NTHI NeOnc Technologies | One Year on NASDAQ (NTHI) | Progress, Pipeline & What’s Next One year after NeOnc Technologies' listing on NASDAQ under the ticker NTHI, NeOnc reflects on key clinical and regulatory milestones achieved as a public company. This video highlights progress across the pipeline, reinforces the company’s strategic positioning, and looks ahead to the next phase of execution, bringing innovative therapies closer to patients who need them most. https://www.youtube.com/watch?v=uxcjTkb2xT8
0 · Reply
focafoca99
focafoca99 Apr. 1 at 7:22 PM
$NTHI packed a lot into this update: NEO212 finished Phase 1, NEO100 Phase 2a is fully enrolled, and the balance sheet got help from a $10 million PIPE anchor.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 29 at 6:38 AM
$NTHI At NeOnc Technologies, we are focused on addressing one of the greatest challenges in modern medicine: effectively treating diseases of the brain. Our work centers on overcoming the blood-brain barrier through innovative delivery approaches, including intranasal therapies designed to transport treatment directly to the brain. With clinical-stage programs such as NEO100 and NEO212, we are advancing new possibilities for patients facing aggressive conditions like glioblastoma. The global need for effective CNS therapies continues to grow, representing a significant and largely unmet market opportunity across oncology and neurology. We remain committed to advancing our pipeline and delivering meaningful impact for patients, partners, and shareholders.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 25 at 9:32 AM
$NTHI A quote from NeOnc Technologies founder, Dr. Thomas Chen, Chief Medical Officer: “The determination of the RP2D at 610 mg is a scientifically significant achievement. It confirms that our bio-conjugation technology allows for high-dose delivery of therapeutic agents with a manageable toxicity profile. We are now positioned to explore the efficacy of this optimized dose in our upcoming Phase 2 expansion.”
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 24 at 11:19 AM
$NTHI 📢 Leadership Update at NeOnc Technologies Holdings Inc NTHI NeOnc announces the appointment of David Choi as Chief Accounting Officer, strengthening the Company’s financial leadership as it advances its clinical programs targeting central nervous system (CNS) cancers. With more than a decade of experience in technical accounting, SEC reporting, and internal controls, David has held leadership roles at Blythe Global Advisors, Grant Thornton, and Ernst & Young, advising public and private companies on complex financial and compliance matters. As NeOnc continues progressing its clinical-stage biotechnology platform and expanding global operations, David will oversee accounting, financial reporting, internal controls, and corporate governance to support the Company’s continued growth. Welcome to the team, David. Read the full press release: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-appoints-david-choi-chief-accounting-officer
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 23 at 11:06 PM
$NTHI
0 · Reply
joe_blough
joe_blough Mar. 23 at 12:55 PM
$NTHI I checked the news & found nothing negative to cause its recent dive, so I checked fintel for short interest, which hasn't changed, except for that going into Dark Pool $$, which I don't time to check but is at 48%. Also shares available to be shorted has increased from 35k to 400k, so I guess it's all going into the Dark Pool. Somebody apparently is trying for a big chunk of this, at a cheap price. It's a shame this behavior is allowed
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 18 at 9:01 AM
$NTHI Amir Heshmatpour, Chairman and CEO of NTHI, on the recently announced data from the dose-escalation portion of our Phase 1/2 clinical trial for NEO212: ”These early efficacy signals, observed even within a dose-escalation safety study, provide meaningful clinical validation of NEO212’s therapeutic potential. With RP2D now established, we believe NeOnc is entering Phase 2 with positive clinical momentum and a clear development pathway.” Read more about this exciting news here: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-reports-phase-1-dose-escalation-results
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 12 at 1:32 PM
$NTHI NeOnc Technologies invites investors and community members to participate in our upcoming Ask Me Anything (AMA) session, led by a member of NeOnc’s leadership team. This AMA is an opportunity to hear directly from leadership and gain deeper insights into NeOnc’s mission to advance innovative therapies for brain and central nervous system cancers. NeOnc is developing novel approaches designed to deliver therapeutics directly to the brain and overcome the challenges of the blood-brain barrier, a major obstacle in treating CNS diseases. 📺 Watch the video and leave your questions in the YouTube comments ahead of the session. Leadership will review and address selected questions during the AMA. 🔗 Watch and comment here: https://www.youtube.com/watch?v=O0npxuoutYg We encourage the community to participate and help shape the discussion by submitting thoughtful questions. #NeOnc #Biotech #BrainCancerResearch #InvestorRelations #AMA
0 · Reply
Latest News on NTHI
NeOnc Provides Business Update and Reports Q4 2025 Financial Results

Apr 1, 2026, 9:00 AM EDT - 4 days ago

NeOnc Provides Business Update and Reports Q4 2025 Financial Results

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Mar 13, 2026, 9:00 AM EDT - 23 days ago

NeOnc Technologies Appoints David Choi as Chief Accounting Officer

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Mar 12, 2026, 8:52 AM EDT - 24 days ago

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

Mar 4, 2026, 8:00 AM EST - 4 weeks ago

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

MRK

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

Feb 27, 2026, 9:00 AM EST - 5 weeks ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Jan 30, 2026, 9:00 AM EST - 2 months ago

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Jan 9, 2026, 7:32 PM EST - 3 months ago

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Reports Updated Clinical Results

Dec 15, 2025, 9:00 AM EST - 3 months ago

NeOnc Technologies Reports Updated Clinical Results

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

Dec 1, 2025, 9:00 AM EST - 4 months ago

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

Nov 13, 2025, 9:00 AM EST - 5 months ago

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

Nov 7, 2025, 9:00 AM EST - 5 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

NeOnc Technologies: From Survival Mode To Expansion Mode

Oct 9, 2025, 2:25 PM EDT - 6 months ago

NeOnc Technologies: From Survival Mode To Expansion Mode

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Oct 9, 2025, 9:00 AM EDT - 6 months ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 29, 2025, 9:00 AM EDT - 6 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

Sep 10, 2025, 9:40 AM EDT - 7 months ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Sep 10, 2025, 9:00 AM EDT - 7 months ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 25, 2025, 9:00 AM EDT - 7 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Aug 11, 2025, 9:00 AM EDT - 8 months ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

Aug 7, 2025, 9:00 AM EDT - 8 months ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

Aug 4, 2025, 9:00 AM EDT - 8 months ago

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Jul 30, 2025, 9:00 AM EDT - 8 months ago

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

Jul 23, 2025, 10:53 AM EDT - 9 months ago

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

Jul 8, 2025, 9:00 AM EDT - 9 months ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

Jun 6, 2025, 9:00 AM EDT - 10 months ago

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

Apr 15, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

Apr 14, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

Apr 10, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Apr 8, 2025, 4:05 PM EDT - 1 year ago

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Mar 31, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Mar 27, 2025, 8:05 AM EDT - 1 year ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

Mar 25, 2025, 8:45 AM EDT - 1 year ago

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

Mar 25, 2025, 8:15 AM EDT - 1 year ago

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

Jan 4, 2025, 12:30 AM EST - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

AERO CAPS CRGT FBGL FLOC INLF INR

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

Oct 7, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

Aug 5, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

Jul 16, 2024, 11:15 AM EDT - 1 year ago

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

Jun 26, 2024, 4:39 PM EDT - 1 year ago

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

May 15, 2024, 11:00 AM EDT - 2 years ago

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

May 9, 2024, 5:30 PM EDT - 2 years ago

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

Mar 30, 2024, 1:00 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

BOLD MMA MNDR NTCL ROTR UBXG WAY

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

Dec 25, 2023, 9:05 AM EST - 2 years ago

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

LGCB MAMO LZMH

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

Dec 20, 2023, 2:38 PM EST - 2 years ago

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

NeOnc_Technologies
NeOnc_Technologies Apr. 4 at 4:37 PM
$NTHI Driving Scientific Innovation into Commercial Impact NeOnc Technologies leverages a robust ecosystem of research, regulatory, and management expertise to accelerate the translation of cutting-edge science from the lab to the clinic and into the marketplace. Watch our full conversation with New To The Street TV here: https://bit.ly/NTTS-NeOncBreaksThroughBrainCancerTreatment #NeOncTechnologies #Quazar #BiotechInnovation #InvestorRelations #MarketImpact
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Apr. 2 at 6:10 PM
$NTHI NeOnc Technologies | One Year on NASDAQ (NTHI) | Progress, Pipeline & What’s Next One year after NeOnc Technologies' listing on NASDAQ under the ticker NTHI, NeOnc reflects on key clinical and regulatory milestones achieved as a public company. This video highlights progress across the pipeline, reinforces the company’s strategic positioning, and looks ahead to the next phase of execution, bringing innovative therapies closer to patients who need them most. https://www.youtube.com/watch?v=uxcjTkb2xT8
0 · Reply
focafoca99
focafoca99 Apr. 1 at 7:22 PM
$NTHI packed a lot into this update: NEO212 finished Phase 1, NEO100 Phase 2a is fully enrolled, and the balance sheet got help from a $10 million PIPE anchor.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 29 at 6:38 AM
$NTHI At NeOnc Technologies, we are focused on addressing one of the greatest challenges in modern medicine: effectively treating diseases of the brain. Our work centers on overcoming the blood-brain barrier through innovative delivery approaches, including intranasal therapies designed to transport treatment directly to the brain. With clinical-stage programs such as NEO100 and NEO212, we are advancing new possibilities for patients facing aggressive conditions like glioblastoma. The global need for effective CNS therapies continues to grow, representing a significant and largely unmet market opportunity across oncology and neurology. We remain committed to advancing our pipeline and delivering meaningful impact for patients, partners, and shareholders.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 25 at 9:32 AM
$NTHI A quote from NeOnc Technologies founder, Dr. Thomas Chen, Chief Medical Officer: “The determination of the RP2D at 610 mg is a scientifically significant achievement. It confirms that our bio-conjugation technology allows for high-dose delivery of therapeutic agents with a manageable toxicity profile. We are now positioned to explore the efficacy of this optimized dose in our upcoming Phase 2 expansion.”
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 24 at 11:19 AM
$NTHI 📢 Leadership Update at NeOnc Technologies Holdings Inc NTHI NeOnc announces the appointment of David Choi as Chief Accounting Officer, strengthening the Company’s financial leadership as it advances its clinical programs targeting central nervous system (CNS) cancers. With more than a decade of experience in technical accounting, SEC reporting, and internal controls, David has held leadership roles at Blythe Global Advisors, Grant Thornton, and Ernst & Young, advising public and private companies on complex financial and compliance matters. As NeOnc continues progressing its clinical-stage biotechnology platform and expanding global operations, David will oversee accounting, financial reporting, internal controls, and corporate governance to support the Company’s continued growth. Welcome to the team, David. Read the full press release: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-appoints-david-choi-chief-accounting-officer
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 23 at 11:06 PM
$NTHI
0 · Reply
joe_blough
joe_blough Mar. 23 at 12:55 PM
$NTHI I checked the news & found nothing negative to cause its recent dive, so I checked fintel for short interest, which hasn't changed, except for that going into Dark Pool $$, which I don't time to check but is at 48%. Also shares available to be shorted has increased from 35k to 400k, so I guess it's all going into the Dark Pool. Somebody apparently is trying for a big chunk of this, at a cheap price. It's a shame this behavior is allowed
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 18 at 9:01 AM
$NTHI Amir Heshmatpour, Chairman and CEO of NTHI, on the recently announced data from the dose-escalation portion of our Phase 1/2 clinical trial for NEO212: ”These early efficacy signals, observed even within a dose-escalation safety study, provide meaningful clinical validation of NEO212’s therapeutic potential. With RP2D now established, we believe NeOnc is entering Phase 2 with positive clinical momentum and a clear development pathway.” Read more about this exciting news here: https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-reports-phase-1-dose-escalation-results
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 12 at 1:32 PM
$NTHI NeOnc Technologies invites investors and community members to participate in our upcoming Ask Me Anything (AMA) session, led by a member of NeOnc’s leadership team. This AMA is an opportunity to hear directly from leadership and gain deeper insights into NeOnc’s mission to advance innovative therapies for brain and central nervous system cancers. NeOnc is developing novel approaches designed to deliver therapeutics directly to the brain and overcome the challenges of the blood-brain barrier, a major obstacle in treating CNS diseases. 📺 Watch the video and leave your questions in the YouTube comments ahead of the session. Leadership will review and address selected questions during the AMA. 🔗 Watch and comment here: https://www.youtube.com/watch?v=O0npxuoutYg We encourage the community to participate and help shape the discussion by submitting thoughtful questions. #NeOnc #Biotech #BrainCancerResearch #InvestorRelations #AMA
0 · Reply
newsfile_corp
newsfile_corp Mar. 12 at 12:52 PM
https://nfne.ws/288256 $NTHI @reportablenews #NASDAQ #Investing
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 11 at 1:35 PM
$NTHI NeOnc Technologies reports Phase 1 Results for Oral NEO212 - Live Conference NeOnc announced measurable anti-tumor activity in Phase 1, providing early clinical confirmation of NEO212’s therapeutic potential and supporting the Company’s progress into the Phase 2 segment of the trial. With the recommended Phase 2 dose now established, the program moves forward into Phase 2 clinical development. 🎥 Watch the conference call: https://lnkd.in/gq2Sh_EK Have a question? Leave it below in the comments, and a member from our leadership team will answer it in our upcoming Ask Me Anything video. #NeOnc #Biotech #BrainCancerResearch #InvestorRelations #AMA
0 · Reply
focafoca99
focafoca99 Mar. 7 at 11:48 PM
$NTHI no spin needed here - first clinical readout plus a clear next-stage path can absolutely wake this ticker up
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Mar. 5 at 10:02 AM
$NTHI We’re thrilled to celebrate our CEO, Amir Heshmatpour, being featured in USA TODAY's list of Top Entrepreneurs Going Into 2026, a testament to visionary leadership and bold innovation shaping the future of biotech. Under Amir’s leadership, NeOnc Technologies continues to push boundaries in cancer research and therapeutic development, from advancing novel treatment platforms to driving strategic growth on the global stage. His commitment to bridging science, strategy, and impact has positioned NeOnc at the forefront of next-generation oncology innovation. 👏 Congratulations to Amir & NeOnc! Here’s to a year of breakthrough science, meaningful progress, and continued impact for patients worldwide. https://www.usatoday.com/story/special/contributor-content/2026/02/23/top-entrepreneurs-going-into-2026/88825698007/
0 · Reply
joe_blough
joe_blough Mar. 4 at 2:33 PM
$NTHI let her rip. I don't expect a moonshot but LEO would be nice
0 · Reply
joe_blough
joe_blough Mar. 4 at 2:32 PM
$NTHI just had an investor conference, where they stated neo212 has $2-3B market, as an assist to TMZ, the current standard of care, and has no apparent toxicity, allowing it to be used, in place of & after TMZ, which becomes toxic with use. Available at neonc.com
0 · Reply
DARKP00L
DARKP00L Mar. 4 at 1:09 PM
$NTHI 08:07 on Mar. 04 2026 NeOnc Technologies Announces Data From Dose-Escalation Portion Of Phase 1/2 Clinical Trial For NEO212, Oral Bio-Conjugated Therapy #tradeideas
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 4 at 1:02 PM
$NTHI - NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
0 · Reply
joe_blough
joe_blough Mar. 3 at 7:56 PM
$NTHI I'm probably the only one who will read this, but they have a conference call, just before market open, tomorrow. Good reviews on their drugs. Probably not a moonshot, but at least LEO
0 · Reply
joe_blough
joe_blough Mar. 3 at 1:11 PM
$NTHI The only thing that scares me about nthi is it's so lightly traded. Love the low short interest.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Feb. 26 at 1:04 PM
$NTHI Clinical durability continues to emerge with intranasal NEO100 in recurrent IDH1-mutant astrocytoma. In the expanded Phase 1/2 cohort (n=25): • 24% radiographic remission • 44% progression-free at 6 months • 36% survival ≥18 months • No significant safety signals observed In a setting with historically limited treatment options, durability of response and tolerability remain key differentiators. Continued patient follow-up will further define the long-term clinical profile of NEO100. #NeOnc #NTHI #NeuroOncology #Biotech #ClinicalDevelopment #OncologyResearch https://neonc.com/neonc-technologies-reports-updated-clinical-results/
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Feb. 24 at 8:40 AM
$NTHI Ask Me Anything | NeOnc Technologies $NTHI At NeOnc Technologies, we believe in transparent communication and direct engagement with our shareholders. We’re hosting a filmed Ask Me Anything (AMA) session featuring a member of NeOnc’s leadership team, and we’d like to hear from you. If you’re a shareholder or follow our progress, please submit your questions in the comments below, and a member of NeOnc Technologies leadership will answer them directly. Topics may include: • Clinical Development Strategy • Platform Science and Differentiation • Regulatory Pathway • Manufacturing and Commercialization Planning • Corporate Strategy and Milestones We will compile questions and address as many as possible in an upcoming recorded AMA video to be shared across our official channels. We look forward to your questions and to continuing the conversation. https://www.youtube.com/watch?v=O0npxuoutYg
1 · Reply